2009's Private Biotech Acquisitions Are a Tale of Two Step-Ups
This article was originally published in Start Up
Executive Summary
Not every acquisition of a venture-backed biotech in 2009 was a structured deal that included earn-outs based on clinical or regulatory milestones. But it sure was close. Thirteen private biotechnology companies were acquired in 2009 and of those deals only a few did not include contingent value rights (CVRs).
You may also be interested in...
BioMarin Refreshes Its Pipeline With ZyStor Acquisition
In a deal weighted heavily toward downstream payments, the orphan drug maker gains a compound that could challenge Genzyme in Pompe disease.
BioMarin Refreshes Its Pipeline With ZyStor Acquisition
In a deal weighted heavily toward downstream payments, the orphan drug maker gains a compound that could challenge Genzyme in Pompe disease.
Biotech Backers Learn To Live With Exit-By-Earn-Out
Even as both public investors and pharma companies more vigorously sniff out biopharma opportunities, exits for venture-backed firms remain scarce. Can risk-sharing acquisitions save the day?